for detecting the common variants. Siegmund et al. [11] extended this method by introducing a prior variant frequency that needs to be specified. Jeng et al. [12] proposed a proportion-adaptive, sparse segment identification procedure that is adaptive to the unknown CNV frequencies.
Despite these novel methods for CNV detection and identification, methods for testing the CNV association are very limited. The current methods for CNV testing fall into two categories. One category assumes that a set of CNVs is known and tests association of these CNVs with complex phenotypes. Barnes et al. [13] developed an approach for testing CNV association using a latentvariable and mixture-modeling framework. However, the current database of all CNVs is still very incomplete and testing only the known CNVs can miss new CNVs that are associated with the phenotype of interest. The other common approach for CNV testing is a two-step approach, where the CNVs are first identified for each sample, and those that appear in multiple samples are then tested using the χ 2 or Fisher's exact test. One limitation of such approaches is that the uncertainty associated with the inferred CNVs is not accounted for in the testing, and the CNVs identified depend on the threshold used. In addition, it is not clear how one should control for the genome-wide error rate, since the number of CNVs to be tested is not known before performing the single-sample CNV analysis. Shi et al. [14] developed a variable threshold exact test for testing disease associations of CNVs randomly distributed in the genome using intensity data from SNP arrays. The test was developed for the scenario that cases are more frequently disrupted by CNVs than controls in a given genomic region, while CNVs are randomly distributed in the region with various boundaries.
In this paper, we propose a new statistical method for identifying trait-associated CNVs. Instead of assuming a known set of CNVs or first identifying the CNVs carried by the samples, the proposed method directly identifies the CNVs that are associated with the trait of interest. Different from a variable threshold exact test that partitions autosomal chromosomes into segments with a predefined length (e.g., 50 SNPs), the proposed procedure scans the genome with intervals of variable lengths and identifies the trait-associated CNVs based on examining the score statistics. Specifically, for a given candidate interval, we first evaluate whether there are any samples that may contain CNVs overlapping with this interval. We consider all candidate intervals of variable lengths and identify the set of intervals that overlaps with the CNVs of at least one sample. We then test for phenotype association only for the intervals in the selected set. The procedure is computationally faster than the two-step approaches, since it only requires scanning the genome once. In addition, since the association test is performed for each interval in the identified set, we overcome the problem of postprocessing the intervals of possible variable lengths identified in a single-sample CNV identification. We show that the procedure can control the genome-wide error rate and also has a high probability of identifying the trait-associated CNVs.
First, we introduce the statistical model and score test for a candidate genomic segment or interval. Then, we present a scanning procedure for identifying trait-associated CNVs and give the theoretical properties. In the Simulation Studies section, we evaluate the performance of our test. Next, we demonstrate our method in identifying the CNVs that are associated with population differentiation. Finally, we conclude giving a brief discussion.
Statistical Model and CNV Association Test
Suppose that we have data on n independent individuals. Let Y i be the phenotype value for the i -th individual and X ij be the observed marker intensity (e.g., the log R ratio from the SNP chip data) for the i -th individual and j -th marker, for i = 1, …, n and j = 1, …, m . Here, Y i can be a binary variable as in case-control studies or a continuous variable, e.g., as in eQTL studies, where Y i can be the expression level of a gene. For the SNP chip data, the observed marker intensity data is the log R ratio, X ij = log 2 ( R obs / R ref ), where R obs represents the total intensity of two alleles at the j -th SNP for the i -th sample, and R ref is the corresponding quantity for a reference sample. When there is no copy number change in a genomic region for individual i , we expect that all X ij s in that region are realizations of a baseline distribution. In the following, for each sample, we normalize the intensity data to have a variance of 1 by dividing the median absolute deviation. Suppose there is a total of q = q m , n CNVs in all n individuals, with q possibly increasing with m , and n is unknown. Let  = { I 1 , …, I q } be the collection of the corresponding CNV segments/intervals. The value X ij in a CNV region deviates from 0 to the negative or positive side depending on whether the region is deleted or duplicated.
Since only a certain proportion of the samples carry a given CNV, we denote the proportion of CNV carriers at I k as π k , 1 ≤ k ≤ q . We assume 
where μ k ≠ 0 represents the mean value of the jump sizes in the k -th CNV region, and σ k may or may not be equal to 1, to reflect the fact that different variations may be introduced by the CNV carriers. Here, π k , μ k and σ k are unknown for each I k ∈ . 
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For a given candidate interval τ and individual i , we summarize the marker intensity data in this interval by the length-standardized sum
Further, we define
for some ν > 0 to indicate whether or not the i -th individual carries some copy number changes in interval τ . Threshold ν will be specified in the next section. To link the carrier status at interval τ to the phenotype, we assume the following generalized linear model (GLM) for phenotype Y i with the likelihood function given by
where
is the link function for Z iτ and Y i , and γ is the dispersion parameter. In this model, α is the intercept coefficient, and β τ is the regression coefficient that associates the possible CNV τ to the mean value of the phenotype. Our goal is to identify the elements in  that have non-zero β coefficients. The identified elements indicate the locations of the trait-associated CNVs.
A Procedure for Identifying the Trait-Associated CNVs and Its Theoretical Properties
Here, we present a scanning procedure for identifying the traitassociated CNVs followed by the theoretical analysis of its type I error controls and power.
A Scanning Procedure for Identifying the Trait-Associated CNVs
Since most of the CNVs are short, we only consider short intervals with a length ≤ L in the sequences of the observed genomewide data. L was chosen to satisfy the following condition:
{distance between I k and I k + 1 }. This condition guarantees that all CNV segments can be covered by some intervals considered in the algorithm, and, at the same time, none of the intervals is long enough to reach more than one CNV segment. Since most CNVs are very short and sparse, condition 5 is easy to be satisfied. In practice, we tend to choose L based on some prior knowledge about the data-generating platforms. For 600K SNP arrays, the typical size of CNVs is fewer than 20 SNPs. We usually choose L = 20. Ideally, we should choose L a little larger than the maximum length of the CNVs. A large L increases the computational time, since mL intervals have to be scanned. In contrast, a small L tends to divide long CNVs into two small contiguous ones. However, postprocessing of the results can easily combine the contiguous CNVs into one CNV. Let  be the collection of all mL intervals of length ≤ L . The threshold in equation 3 is set at 2 log . mL (6) This is the same threshold used by Jeng et al. [7] for detecting CNVs in a long sequence of m genome-wide observations for one individual. A threshold at this level optimally controls the false positive CNV identification for each individual asymptotically under the assumption of additive Gaussian noises with equal variances. It can separate the CNVs from the noise as long as the signal segments are in the identifiable region [7] . This greatly reduces the number of intervals that need to be considered for association test. We first select the intervals in  that have Z iτ = 1 for at least one individual and denote the collection of such intervals as
.
Let r ˆ = || be the total number of such intervals. Note that collection  is much smaller than  and only includes intervals where copy number changes are observed in the samples. As a second step, based on the GLM 4, we test
for any τ ∈  using the score statistic
where S Z τ and S Y are the sample standard deviations of Z τ and Y .
The score statistic S n , τ has an asymptotic standard normal distribution under H τ 0 for τ ∈ . Therefore, we reject
where λ is a threshold determined by the limiting distribution of S n , τ under H τ 0 and the number of the score tests performed. We set 2 logr
in order to control the genome-wide error. This threshold is chosen based on extreme value theory of standard normal random variable. We have max 2 log n,Ŝ r with a probability tending to 1 under the null hypothesis of no phenotype-associated CNVs. Our scanning procedure, CNVtest, identifies all elements in  that are significantly associated with the trait value Y , by selecting the intervals in  with their absolute score statistics above λ and achieving local maximums. Specifically, CNVtest involves the following steps: 
Theoretical Results on Error Control and Power Analysis
Recall that q = q m , n is the total of number of true CNVs in n individuals. We assume log q = o (log m ) and q → ∞ as n → ∞ , 
for some ε > 0. Condition 11 is required, since Jeng et al. [7] showed that this is the detection boundary for any statistical procedure to identify the CNVs. This condition assumes that our combined CNV set  only includes the statistically detectable CNVs.
The following theorem states that with a large probability, CNVtest controls the genome-wide error rate. In other words, CNVtest does not select the null intervals in . Theorem 1 . Assume conditions 1, 4, 10, 11 and 5. Let  0 = { τ ∈ : τ ∩ I k = Ø for all I k ∈ } be the set of intervals that do not overlap with any of the CNVs in the true CNV set . Then
This theorem implies that the probability of CNVtest identifying wrong trait-associated CNVs approaches 0, when the sample size is large enough. Our proof of theorem 1 in the Appendix implies that P ( ∃ τ ∈ I 0 : τ ∈ I ˆ ) is asymptotically bounded by
which decreases to 0 given conditions 5 and 10. Therefore, the convergence rate is asymptotically faster than
where q is the number of CNVs, m the dimensionality/total number of markers and L the length of the longest scanning interval. We next studied the power of CNVtest in identifying the traitassociated CNVs. A key quantity that is related to power is
where g () · and α are defined in GLM 4. 
The proof of this theorem is given in the Appendix. The first part of theorem 2 shows that, with a large probability, I k is selected to enter the candidate set  (1) in the algorithm. The second part shows that, with a large probability, the score statistic of the true segment I k dominates the score statistics of other intervals overlapping with I k , so that the true segment I k can be identified by the algorithm. The additional conditions in the second part of the theorem imply the monotonicity of the mean value of S n,τ with respect to how much τ overlaps with I k .
Simulation Studies
We present Monte Carlo simulations to evaluate the performance of CNVtest. We simulated data sets with n = 1,000 individuals, of whom 500 are cases and 500 are controls. For each individual, we generated the log R intensity values at m = 5,000 markers. We simulate two CNVs, one null CNV with the same frequency of 0.15 in both the cases and controls, the other disease-associated CNV has a frequency of 0.10 in the controls and a frequency of p = 0.15, 0.20, 0.25 and 0.30 in the case group. The length of both CNV segments is set to s = 10. The first model (Disease I) assumes that the disease-associated CNVs have the same genomic locations in all samples. For the second model (Disease II), instead of assuming that all carriers of the disease-associated CNVs have the segments at exactly the same genomic locations, we considered the case when the locations of the CNVs vary within an interval of length 15, where CNV segments with length s = 10 are randomly selected within a fixed interval of length 15. Therefore, the CNV carriers have overlapping but not exactly the same CNV segments. We considered the shifted mean of the CNVs of μ = 1.5, 1.75, 2, 2.25 and 2.5. Each observation X ij , i = 1, …, n , j = 1, …, m is generated from N ( A ij , 1). If marker j is located in a CNV segment and the i-th individual is a carrier of the variant, A ij = μ ; otherwise, A ij = 0. The phenotype Y i , i = 1, …, n takes the value of 1 and 0 for case and control individual, respectively.
We applied CNVtest with L = 15 and 2 log 4 74 mL .
to select the disease-associated CNVs. The simulations were repeated 50 times. To evaluate the performance of CNVtest, we considered three summary statistics ( SS , EP and EO ), where SS is the score statistic calculated in equation 8 for an interval, EP is the empirical power, which is equal to the proportion of times that a disease-associated segment is selected in 50 replications and EO is the empirical over-selection, which is equal to the proportion of simulations that an interval that does not overlap with the disease-associated CNV is selected. The estimated standard errors of the means of these statistics are derived by calculating the standard deviation of 500 bootstrap means of 50 results from 50 replications. We first examined the effects of CNV jump size μ on the performance of CNVtest, where we fixed the CNV carries' frequency at 20% in cases and at 10% in controls. Figure 1 a shows SS calculated for the true CNV intervals for the null CNV and also the disease-associated CNVs as we changed the jump size of the CNVs from 1.5 to 2.5, together with the threshold level determined by equation 9. We observe that SS for the null CNV is constant and is always much smaller than the threshold. On the other hand, SS for the disease-associated CNVs increases as μ increases. In addition, shifts in the exact CNV boundaries lead to smaller SS , especially when μ is small. Figure 1 c shows EP of CNVtest for identifying the disease-associated CNVs. As expected, larger μ leads to a high power of identifying the true CNVs. Again, shifts in the exact CNV boundaries lead to a slight loss of power, especially when μ is small. We observed that EO is always 0 for all data sets simulated, and it is not affected by the values of μ .
We then fixed μ = 2.0 and examined how the proportion of carriers in cases affects the power to identify the disease-associated CNVs ( fig. 1 d) . Figure 1 b shows SS , evaluated at the true CNV intervals for the null CNV and also the disease-associated CNVs, as we changed the proportion of CNV carriers in cases from 15 to 30%, together with the threshold level determined by equation 9. We observed that SS for the null CNV is constant and is always much smaller than the threshold. On the other hand, SS for the disease-associated CNVs increases as the proportion of carriers in cases increases. Again, for all simulations, we did not observe any false identifications. 
Application to Population Differentiation CNV Study
Redon et al. [15] presented the first genome-wide global variation analysis of DNA copy number in the human genome, where DNA of EBV-transformed lymphoblastoid cell lines of the 270 HapMap samples were screened for CNVs, using clone-based comparative genomic hybridization (Whole Genome TilePath) array consisting of 27,000 large-insert clones. To demonstrate our method, we consider data from two populations: 89 individuals of European descent from Utah (CEU) versus 45 unrelated Japanese individuals from Tokyo (JPT) plus 45 unrelated Han Chinese individuals from Beijing (CHB). Our goal was to identify the genomic regions that show differences in copy number between the CEU and the Asian individuals (JPT+CHB). Such population differentiation in CNV can provide important insights into genetic diversity and evolution.
For each individual, we first standardized the clone intensity data by mean and variance calculated for this individual. Since one clone covers a longer region than the SNP data, we chose L = 10 in our CNVtest so that the largest CNV covers at most 10 clones. Here, we considered both duplication and deletion CNVs and modified equation 3 by Z respectively. CNVtest identified five duplication CNVs and one deletion CNV that showed different frequencies between the European and Asian populations. Table 1 shows their clone locations, sizes, overlapping genes and their SS defined in equation 8. Figure 2 shows the scatter-plots of the length-adjusted sum of clone-intensity statistics defined in equation 2 for each of the samples for each of the six identified CNV regions, clearly indicating the differences in the carrier frequencies. To show that the clones in the identified CNV regions indeed have different intensities for samples in these two different populations, figure 3 provides the observed clone intensities for the clone within the identified CNV regions and those that are outside for each of the samples. Again, the identified CNV regions indeed show some differences in clone intensities from their neighboring clones. Note that the two CNVs on chromosome 9 are very close to each other and have similar intensity patterns in the samples. It is likely that they form a large CNV; this is due to the fact that we chose L = 10 in CNVtest. However, as in any CNV analysis, a postprocessing step may simply combine these two CNVs into one.
Redon et al. [15] reported two CNVs that exhibit the highest population differentiation between CEU and JPT+CHB; one of which, the duplication CNV on chromosomes 17 that includes gene MAPT, is also identified by CNVtest. CNVtest did not identify the CNV on chro- 155 cation CNVs that showed very different frequencies. These CNVs includes all 6 CNVs that were reported in Redon et al. [15] to have the highest population differentiation. When comparing YRI and JPT+CHB individuals, CNVtest identified 2 deletion CNVs and 12 duplication CNVs, including 2 CNVs that were reported in Redon et al. [15] to have the highest population differentiation.
Conclusion and Discussion
We have developed a new statistical method, CNVtest, for genome-wide CNV association studies. Compared with the commonly used two-step approaches, CNVtest is computationally much faster, since the genome is only scanned once. The computational complexity of this method is the same as the likelihood ratio selector by Jeng et al. [7] and the multiple sample CNV analysis procedure by Jeng et al. [12] , all in the order of O ( mL ). In addition, it avoids the often trouble-some task of determining which CNV regions should be tested for association and how to adjust for multiple comparisons. The method is particularly effective when the CNV regions from the different carriers do not exactly cover the same intervals. CNVtest is also flexible and can be applied to identify CNV associations of different phenotypes through the use of the GLMs. One can also easily extend CNVtest to account for dosage effect by simply replacing the Z iτ in equation 3 by
CNVtest can also be applied to identify CNV associations using the read-depth data from next-generation sequencing. One can use the local median transformation procedure proposed by Cai et al. [16] to transform the read-depth data to approximately normally distributed data and directly apply CNVtest to the transformed data. We expect to have similar power and genome-wide error control as the intensity-based data. 
Proof of Theorem 2
Given by the asymptotic results for SS , S n , I k is asymptotically normally distributed with mean 156 for some C > 0, where the second inequality is due to equation 13, and the last step is due to η = O (1) and Mills's ratio. Therefore, H I k 0 is rejected with a probability approaching 1. Now consider the rest of theorem 2. Given the asymptotic results of SS , P ( S n , I k > S n , τ ) is approximately equal to 
and
Note that given conditions 1 and 2, we have 
